Core Framework & Diagram Where Is Immunology Headed?
July 24, 20261 Min Read How Has Immunology Changed Human Lifespan?
July 24, 2026We are standing at a watershed
—— The next thirty years will be immunology's critical era of moving from understanding to designing.
I. Engineered design of immune systems: next-generation cell therapy
CAR-T therapy (Article 160) was the first-generation product of immune system engineering — it proved genetic modification can give T cells entirely new recognition abilities. But first-generation CAR-T is still a rough engineering product in multiple respects: it can only recognize a single target, susceptible to relapse from target loss; it can't autonomously regulate activation intensity, prone to causing CRS; it exhausts in solid tumors' immunosuppressive microenvironments; its manufacturing is patient-individualized, with very high costs. Next-generation immune cell engineering is systematically solving these problems.
Multi-target CAR-T simultaneously recognizes multiple tumor antigens — even if tumors downregulate one target, other targets can still trigger attack, reducing antigen-escape relapses. Logic-gated CAR uses synthetic biology to design 'AND gates' (only attack when simultaneously recognizing antigen A and antigen B), 'NOT gates' (stop when identifying normal cell marker B despite recognizing antigen A), and other logic gates, improving tumor specificity and reducing normal tissue targeting toxicity. 'Armored' CAR-T: beyond the CAR gene, additionally introduces cytokine genes (IL-15, IL-12, or IL-21) so CAR-T cells can self-secrete pro-survival signals in the tumor microenvironment, combating immunosuppressive microenvironments, extending activity in solid tumors. Universal allogeneic CAR-T: through CRISPR editing of healthy donor T cells, deleting TCR (preventing graft-versus-host disease) and HLA (preventing host rejection), enabling standardized mass production, reducing costs from hundreds of thousands of dollars to thousands of dollars. More radical engineering attempts include introducing synthetic receptors into immune cells that can respond to artificially designed signal molecules (rather than natural antigens), enabling externally precise control of cell activity — similar to installing a remote control on T cells that can be opened when needed and closed when needed, greatly improving safety and controllability.
2. Aging immunology: the possibility of immune system rejuvenation
Immune system aging (immunosenescence) is one of current biological gerontology's most active research frontiers. With aging, the immune system undergoes: thymic atrophy (reduced new T cell production), decreased T cell diversity (narrowed range of recognizable antigens), decreased NK cell function (weakened tumor surveillance), increased chronic low-level inflammation ('inflammaging'), and weakened vaccine response capacity. These changes are one of the core reasons elderly people are more vulnerable to infections and tumors. Research on reversing immune aging has made early progress in several directions. Thymus regeneration: thymic atrophy is a key driver of immune aging. In 2019, a small clinical study (TRIIM trial) showed growth hormone + metformin + DHEA combination therapy could to some extent reverse thymic atrophy in healthy elderly (measured by MRI), with participants' biological age 'reversing' about 2.5 years on average. This research had extremely small sample size and needs larger-scale validation, but provided human-level proof of concept. Senescent cell clearance: senescent cells are an important source of immune cell function decline and chronic inflammation. Drugs targeting senescent cell clearance (senolytic drugs, like dasatinib + quercetin combination) show improved immune function and extended healthy lifespan in animal models, with multiple human clinical trials underway. Epigenetic reprogramming: based on Shinya Yamanaka's (2012 Nobel) iPS technology, researchers are exploring whether partial epigenetic reprogramming can erase cells' 'aging records' while preserving cell identity, restoring their functional vitality.
3. Neuroimmunology: the two-way conversation between brain and immune system
Neuroimmunology is rapidly transforming our understanding of neurodegenerative diseases, mood disorders, and brain health. Microglia are the brain's resident immune cells, constituting central nervous system immune defense's main force. They participate in 'synaptic pruning' during normal development — clearing no-longer-needed neural synaptic connections, helping brain circuits optimize. But in neurodegenerative diseases like Alzheimer's and Parkinson's, microglia enter an over-activated state, not only clearing diseased cells but also beginning to attack normal synapses and neurons, accelerating neurodegeneration. The 2023 FDA-approved Alzheimer's drug lecanemab reduces cognitive decline by clearing amyloid-beta protein plaques — its mechanism is in some sense 'teaching' the peripheral immune system (through monoclonal antibodies) to help the brain clear debris, then microglia complete the final cleanup. This is the first step of neuroimmunology moving from basics to clinic. In mental health, increasingly more evidence shows depression, bipolar disorder, and other mood disorders are closely related to immune system chronic activation (particularly elevated IL-6, TNF-α and other pro-inflammatory cytokines). Some treatment-resistant depression patients show symptom improvement after anti-inflammatory treatment — suggesting 'inflammatory depression' may be a distinct subtype requiring targeted immune intervention rather than just neurotransmitter regulation.
4. Personalized immune medicine: every person is an immunological individual
Current medicine is increasingly recognizing: two 'healthy' people can have enormously different baseline immune system states — different T cell subpopulation proportions, different NK cell activity, different inflammation baselines, different vaccine response patterns. Personalized immune medicine's vision is to systematically measure each person's immune characteristics ('immunophenotype'), combined with genomics, microbiomics, and metabolomics data, plus AI's integrated analysis of all this data, building personalized immune health profiles, predicting disease risks, and formulating individualized prevention and intervention plans. Stanford University's Michael Snyder-led early research showed that through multi-year multi-omics monitoring of the same person in healthy state, molecular early-warning signals of many diseases (like type 2 diabetes, cardiovascular disease) can be detected before clinical symptoms appear, including early changes in the immune system. In vaccines, personalized significance is equally important: research shows different individuals can differ tenfold to a hundredfold in antibody titers against the same vaccine. Future vaccination strategies may no longer be 'same dose for everyone' but adjusted based on individual immune phenotype — adjusting dose, adjuvant type, and immunization intervals for more efficient, safer vaccination.
5. AI and immunology: new tools for understanding complex systems
Artificial intelligence (particularly deep learning and large language models) is accelerating immunology research in multiple ways. AlphaFold2 protein structure prediction has completely transformed antibody, cytokine receptor, and MHC-antigen complex structural research, enabling rapid prediction of any protein-protein interaction interface, accelerating vaccine antigen design and antibody engineering. In single-cell data analysis, AI algorithms enable processing super-large-scale datasets of tens of thousands of cells and tens of thousands of genes, extracting biologically meaningful patterns. In clinical prediction models, AI prediction algorithms based on immune markers are being used to predict patient responses to chemotherapy, immunotherapy, and vaccines, helping clinicians make more precise treatment decisions. AI's application in immunology essentially addresses one core problem: the immune system is a highly nonlinear complex system where any single variable change can produce unexpected chain reactions in other parts. Traditional reductionist methods (studying one molecule or pathway at a time) can't capture this holistic complex dynamics. AI's capacity to simultaneously process multi-dimensional, large-scale data, discovering cross-dimensional patterns imperceptible to human intuition — is precisely the capability most needed for understanding immune system complexity.
Frequently Asked Questions